FDA Calls for Public Comments on Wider Distribution of Naloxone for Opioid Overdose Fatality Prevention

The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), in collaboration with the Office of the Assistant Secretary for Health, National Institutes of Drug

Abuse, and the Centers for Disease Control and Prevention, is announcing a scientific workshop to initiate a public discussion about the potential value of making naloxone more widely available outside of conventional medical settings to reduce the incidence of opioid overdose fatalities.


Source: Federal Register / Vol. 76, No. 222 / Thursday, November 17, 2011 / Notices